(MedPage Today) — CHICAGO — Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial.
The 400-mg dose cut Lp(a) by 93.9 percentage points compared with placebo from…
Source link : https://www.medpagetoday.com/meetingcoverage/acc/114898
Author :
Publish date : 2025-03-31 18:47:00
Copyright for syndicated content belongs to the linked Source.
